

Vasim Farooq

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5891834/publications.pdf>

Version: 2024-02-01

133
papers

6,568
citations

50276

46
h-index

69250

77
g-index

134
all docs

134
docs citations

134
times ranked

5353
citing authors

#	ARTICLE	IF	CITATIONS
1	Five-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with <i>de novo</i> three-vessel disease: final results of the SYNTAX II study. <i>European Heart Journal</i> , 2022, 43, 1307-1316.	2.2	54
2	Defining Percutaneous Coronary Intervention Complexity and Risk. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 39-49.	2.9	33
3	The Impact of Intracoronary Imaging on PCI Outcomes in Cases Utilising Rotational Atherectomy: An Analysis of 8,417 Rotational Atherectomy Cases from the British Cardiovascular Intervention Society Database. <i>Journal of Interventional Cardiology</i> , 2022, 2022, 1-9.	1.2	0
4	Rotational Atherectomy Complicated by Coronary Perforation Is Associated With Poor Outcomes: Analysis of 10,980 Cases From the British Cardiovascular Intervention Society Database. <i>Cardiovascular Revascularization Medicine</i> , 2021, 28, 9-13.	0.8	11
5	The impact of coronary perforation in percutaneous interventions involving the left main stem coronary artery in the United Kingdom 2007â€“2014: Insights from the British Cardiovascular Intervention Society database. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, E179-E185.	1.7	2
6	Combined use of rotational and excimer LASER coronary atherectomy (RASER) during complex coronary angioplastyâ€”An analysis of cases (2006â€“2016) from the British Cardiovascular Intervention Society database. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, E911-E918.	1.7	4
7	Excimer laser coronary atherectomy during complex PCI: An analysis of 1,471 laser cases from the British Cardiovascular Intervention Society database. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, E653-E660.	1.7	10
8	Vascular complications associated with intraaortic balloon pump supported percutaneous coronary intervention (PCI) and clinical outcomes from the British Cardiovascular Intervention Society National PCI Database. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E53-E61.	1.7	0
9	Are Higher Operator Volumes for Unprotected Left Main Stem Percutaneous Coronary Intervention Associated With Improved Patient Outcomes?. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008782.	3.9	19
10	Usefulness of the updated logistic clinical SYNTAX score after percutaneous coronary intervention in patients with prior coronary artery bypass graft surgery: Insights from the GLOBAL LEADERS trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E516-E526.	1.7	5
11	Clinical Implication of Quantitative Flow Ratio After Percutaneous Coronary Intervention for 3-Vessel Disease. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2064-2075.	2.9	71
12	Impact of postâ€“procedural minimal stent area on 2â€“year clinical outcomes in the SYNTAX II trial. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, E225-E234.	1.7	26
13	Angiography-Derived Fractional Flow Reserve in the SYNTAX II Trial. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 259-270.	2.9	46
14	Fractional Flow Reserve Derived From Computed Tomographic Angiography in Patients With Multivessel CAD. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2756-2769.	2.8	92
15	Cherry-Picking Historical Data to Legitimize Contemporary Practice. <i>Journal of the American College of Cardiology</i> , 2017, 69, 404-408.	2.8	3
16	Geographical Difference of the Interaction of Sex With Treatment Strategy in Patients With Multivessel Disease and Left Main Disease. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	3.9	31
17	Chronic Total Occlusions. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 889-891.	2.9	0
18	Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study. <i>European Heart Journal</i> , 2017, 38, 3124-3134.	2.2	244

#	ARTICLE	IF	CITATIONS
19	Appropriateness of myocardial Revascularization assessed by the SYNTAX score II in a country without cardiac Surgery facilities; PROUST study. International Journal of Cardiology, 2017, 227, 478-484.	1.7	15
20	Feasibility of hybrid off pump artery bypass grafting and transaortic transcatheter aortic valve implantation: A case series. Catheterization and Cardiovascular Interventions, 2017, 89, 1273-1279.	1.7	8
21	Outcomes After Percutaneous Coronary Intervention or Bypass Surgery in Patients With Unprotected Left Main Disease. Journal of the American College of Cardiology, 2016, 68, 999-1009.	2.8	95
22	Response by Farooq et al to Letter Regarding Article, "Relationship Between Femoral Vascular Closure Devices and Short-Term Mortality From 271 845 Percutaneous Coronary Intervention Procedures Performed in the United Kingdom Between 2006 and 2011: A Propensity Score-Corrected Analysis From the British Cardiovascular Intervention Society". Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	1
23	Bioresorbable scaffolds: a new paradigm in percutaneous coronary intervention. BMC Cardiovascular Disorders, 2016, 16, 38.	1.7	57
24	Relationship Between Femoral Vascular Closure Devices and Short-Term Mortality From 271 845 Percutaneous Coronary Intervention Procedures Performed in the United Kingdom Between 2006 and 2011. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	16
25	Balancing idealism with realism to safeguard the welfare of patients: The importance of Heart Team led decision-making in patients with complex coronary artery disease. Indian Heart Journal, 2016, 68, 1-5.	0.5	3
26	Forward and back aspiration during ST-elevation myocardial infarction: a feasibility study. EuroIntervention, 2016, 11, e1639-e1648.	3.2	9
27	Tools and Techniques - Clinical: SYNTAX score II calculator. EuroIntervention, 2016, 12, 120-123.	3.2	12
28	Rationale and design of the SYNTAX II trial evaluating the short to long-term outcomes of state-of-the-art percutaneous coronary revascularisation in patients with de novo three-vessel disease. EuroIntervention, 2016, 12, e224-e234.	3.2	23
29	Cost-effectiveness of percutaneous coronary intervention versus bypass surgery from a Dutch perspective. Heart, 2015, 101, 1980-1988.	2.9	15
30	Neoatherosclerosis, plaque rupture and very late stent thrombosis of a first generation drug eluting stent treated with aspiration thrombectomy and newer generation drug eluting stent implantation. International Journal of Cardiology, 2015, 201, 648-649.	1.7	1
31	Long-term forecasting and comparison of mortality in the Evaluation of the Xience Everolimus Eluting Stent vs. Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial: prospective validation of the SYNTAX Score II. European Heart Journal, 2015, 36, 1231-1241.	2.2	98
32	Validation of the SYNTAX Revascularization Index to Quantify Reasonable Level of Incomplete Revascularization After Percutaneous Coronary Intervention. American Journal of Cardiology, 2015, 116, 174-186.	1.6	29
33	Risk stratification in 3-vessel coronary artery disease: Applying the SYNTAX Score II in the Heart Team Discussion of the SYNTAX II trial. Catheterization and Cardiovascular Interventions, 2015, 86, E229-38.	1.7	19
34	Validity of SYNTAX score II for risk stratification of percutaneous coronary interventions: A patient-level pooled analysis of 5433 patients enrolled in contemporary coronary stent trials. International Journal of Cardiology, 2015, 187, 111-115.	1.7	26
35	Bypass Grafting Versus Percutaneous Intervention—Which Is Better in Multivessel Coronary Disease: Lessons From SYNTAX and Beyond. Progress in Cardiovascular Diseases, 2015, 58, 316-334.	3.1	7
36	Estimates of absolute treatment benefit for individual patients required careful modeling of statistical interactions. Journal of Clinical Epidemiology, 2015, 68, 1366-1374.	5.0	34

#	ARTICLE	IF	CITATIONS
37	Recurrent Balloon Rupture During Transcatheter Aortic Valve Replacement (TAVR) â€“ Implication for Access Site Choice. Heart Lung and Circulation, 2015, 24, e193-e194.	0.4	5
38	Serial optical coherence tomography of drug-eluting stent in-stent restenosis treated with the Absorb bioresorbable scaffold: an effective treatment?. EuroIntervention, 2015, 10, e1-e1.	3.2	2
39	Clinical outcome of patients with stable ischaemic heart disease as compared to those with acute coronary syndromes after percutaneous coronary intervention. EuroIntervention, 2015, 11, 171-179.	3.2	9
40	The triad of residual ischaemia, plaque burden, and plaque vulnerability: a known known?â€ a known unknown?...or an unknown unknown?. EuroIntervention, 2015, 11, 611-619.	3.2	3
41	Circumferential distribution of the neointima at six-month and two-year follow-up after a bioresorbable vascular scaffold implantation: a substudy of the ABSORB Cohort B Clinical Trial. EuroIntervention, 2015, 10, 1299-1306.	3.2	20
42	Bioresorbable vascular scaffold treatment induces the formation of neointimal cap that seals the underlying plaque without compromising the luminal dimensions: a concept based on serial optical coherence tomography data. EuroIntervention, 2015, 11, 746-756.	3.2	42
43	Response to Letter Regarding Article, â€œQuantification of Incomplete Revascularization and Its Association With Five-Year Mortality in the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) Trial: Validation of the Residual SYNTAX Scoreâ€• Circulation, 2014, 129, e355-6.	1.6	1
44	Coronary evaginations are associated with positive vessel remodelling and are nearly absent following implantation of newer-generation drug-eluting stents: an optical coherence tomography and intravascular ultrasound study. European Heart Journal, 2014, 35, 795-807.	2.2	67
45	Short- and Long-Term Implications of a Bioresorbable Vascular Scaffold Implantation on the Local Endothelial Shear Stress Patterns. JACC: Cardiovascular Interventions, 2014, 7, 100-101.	2.9	11
46	The SYNTAX score and its clinical implications. Heart, 2014, 100, 169-177.	2.9	75
47	Effect of the Endothelial Shear Stress Patterns on Neointimal Proliferation Following Drug-Eluting Bioresorbable Vascular Scaffold Implantation. JACC: Cardiovascular Interventions, 2014, 7, 315-324.	2.9	108
48	Prognostic Value of Site SYNTAX Score and Rationale for Combining Anatomic and Clinical Factors in Decision Making. Journal of the American College of Cardiology, 2014, 64, 423-432.	2.8	48
49	Widening clinical applications of the SYNTAX Score. Heart, 2014, 100, 276-287.	2.9	64
50	Predictive Performance of SYNTAX Score II in Patients With Left Main and Multivessel Coronary Artery Disease. Circulation Journal, 2014, 78, 1942-1949.	1.6	64
51	Comparison of acute gain and late lumen loss after PCI with bioresorbable vascular scaffolds versus everolimus-eluting stents: an exploratory observational study prior to a randomised trial. EuroIntervention, 2014, 10, 672-680.	3.2	30
52	Lessons from acute and late scaffold failures in the ABSORB EXTEND trial: have we really learned them all?. EuroIntervention, 2014, 10, 419-423.	3.2	0
53	Assessment of plaque evolution in coronary bifurcations located beyond everolimus eluting scaffolds: serial intravascular ultrasound virtual histology study. Cardiovascular Ultrasound, 2013, 11, 25.	1.6	7
54	Progress in Treatment by Percutaneous Coronary Intervention: The Stent of the Future. Revista Espanola De Cardiologia (English Ed), 2013, 66, 483-496.	0.6	34

#	ARTICLE	IF	CITATIONS
55	Prediction of 1-Year Mortality in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2013, 6, 737-745.	2.9	54
56	SYNTAX score II – Authors' reply. Lancet, The, 2013, 381, 1899-1900.	13.7	13
57	Complex Coronary Artery Disease. JACC: Cardiovascular Interventions, 2013, 6, 1023-1025.	2.9	4
58	Short-Term and Long-Term Clinical Impact of Stent Thrombosis and Graft Occlusion in the SYNTAX Trial at 5 Years. Journal of the American College of Cardiology, 2013, 62, 2360-2369.	2.8	62
59	Clinical and Angiographic Characteristics of Patients Likely to Have Vulnerable Plaques. JACC: Cardiovascular Imaging, 2013, 6, 1263-1272.	5.3	67
60	Edge Vascular Response After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2013, 6, 211-221.	2.9	31
61	Impact of 3-Dimensional Bifurcation Angle on 5-Year Outcome of Patients After Percutaneous Coronary Intervention for Left Main Coronary Artery Disease. JACC: Cardiovascular Interventions, 2013, 6, 1250-1260.	2.9	47
62	Incidence and Short-Term Clinical Outcomes of Small Side Branch Occlusion After Implantation of an Everolimus-Eluting Bioresorbable Vascular Scaffold. JACC: Cardiovascular Interventions, 2013, 6, 247-257.	2.9	98
63	Intracoronary Optical Coherence Tomography and Histology of Overlapping Everolimus-Eluting Bioresorbable Vascular Scaffolds in a Porcine Coronary Artery Model. JACC: Cardiovascular Interventions, 2013, 6, 523-532.	2.9	84
64	Incidence, correlates, and significance of abnormal cardiac enzyme rises in patients treated with surgical or percutaneous based revascularisation. International Journal of Cardiology, 2013, 168, 5287-5292.	1.7	15
65	In vivo three dimensional optical coherence tomography. A novel imaging modality to visualize the edge vascular response. International Journal of Cardiology, 2013, 164, e35-e37.	1.7	5
66	“Cherry-Picking” Patients for Randomized, Controlled Trials – Reliving the Past. Journal of the American College of Cardiology, 2013, 61, 2492.	2.8	11
67	Future perspectives in transcatheter aortic valve implantation. International Journal of Cardiology, 2013, 168, 11-18.	1.7	20
68	Improved Safety and Reduction in Stent Thrombosis Associated With Biodegradable Polymer-Based Biolimus-Eluting Stents Versus Durable Polymer-Based Sirolimus-Eluting Stents in Patients With Coronary Artery Disease. JACC: Cardiovascular Interventions, 2013, 6, 777-789.	2.9	296
69	CT-SYNTAX Score. JACC: Cardiovascular Imaging, 2013, 6, 413-415.	5.3	62
70	The Negative Impact of Incomplete Angiographic Revascularization on Clinical Outcomes and Its Association With Total Occlusions. Journal of the American College of Cardiology, 2013, 61, 282-294.	2.8	257
71	Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet, The, 2013, 381, 639-650.	13.7	679
72	Bioresorbable scaffolds: Current knowledge, potentialities and limitations experienced during their first clinical applications. International Journal of Cardiology, 2013, 167, 11-21.	1.7	56

#	ARTICLE	IF	CITATIONS
73	Clinical outcomes after zotarolimus and everolimus drug eluting stent implantation in coronary artery bifurcation lesions: insights from the RESOLUTE All Comers Trial. Heart, 2013, 99, 1267-1274.	2.9	36
74	Three-dimensional optical frequency domain imaging in conventional percutaneous coronary intervention: the potential for clinical application. European Heart Journal, 2013, 34, 875-885.	2.2	54
75	Quantification of Incomplete Revascularization and its Association With Five-Year Mortality in the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) Trial Validation of the Residual SYNTAX Score. Circulation, 2013, 128, 141-151.	1.6	326
76	Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial. Heart, 2013, 99, 98-105.	2.9	72
77	Impact of overlapping newer generation drug-eluting stents on clinical and angiographic outcomes: pooled analysis of five trials from the international Global RESOLUTE Program. Heart, 2013, 99, 626-633.	2.9	31
78	Bioresorbable scaffolds in the treatment of coronary artery disease. Medical Devices: Evidence and Research, 2013, 6, 37.	0.8	17
79	The CABG SYNTAX Score - an angiographic tool to grade the complexity of coronary disease following coronary artery bypass graft surgery: from the SYNTAX Left Main Angiographic (SYNTAX-LE MANS) substudy. EuroIntervention, 2013, 8, 1277-1285.	3.2	71
80	Clinical and angiographic outcomes following first-in-man implantation of a novel thin-strut low-profile fixed-wire stent: the Svelte Coronary Stent Integrated Delivery System first-in-man trial. EuroIntervention, 2013, 9, 125-134.	3.2	8
81	Emerging technologies: polymer-free phospholipid encapsulated sirolimus nanocarriers for the controlled release of drug from a stent-plus-balloon or a stand-alone balloon catheter. EuroIntervention, 2013, 9, 148-156.	3.2	93
82	Observations from the CREDO-Kyoto three-vessel disease registry: can one adjust for the unadjustable?. EuroIntervention, 2013, 9, 419-421.	3.2	3
83	The edge vascular response following implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold and the XIENCE V metallic everolimus-eluting stent. First serial follow-up assessment at six months and two years: insights from the first-in-man ABSORB Cohort B and SPIRIT II trials. EuroIntervention, 2013, 9, 709-720.	3.2	17
84	In vivo assessment of the three-dimensional haemodynamic micro-environment following drug-eluting bioresorbable vascular scaffold implantation in a human coronary artery: fusion of frequency domain optical coherence tomography and angiography. EuroIntervention, 2013, 9, 890-890.	3.2	17
85	Revisiting: â€œComparison of intravascular ultrasound versus angiography-guided drug-eluting stent implantation: a meta-analysis of one randomised trial and ten observational studies involving 19,619 patientsâ€ EuroIntervention, 2013, 9, 891-892.	3.2	7
86	The coronary artery bypass graft SYNTAX Score: final five-year outcomes from the SYNTAX-LE MANS left main angiographic substudy. EuroIntervention, 2013, 9, 1009-1010.	3.2	15
87	Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy?. European Heart Journal, 2012, 33, 1325-1333.	2.2	138
88	Incidence and multivariable correlates of long-term mortality in patients treated with surgical or percutaneous revascularization in the Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery (SYNTAX) trial. European Heart Journal, 2012, 33, 3105-3113.	2.2	119
89	Vascular Compliance Changes of the Coronary Vessel Wall After Bioresorbable Vascular Scaffold Implantation in the Treated and Adjacent Segments. Circulation Journal, 2012, 76, 1616-1623.	1.6	57
90	Analysis of 1-year virtual histology changes in coronary plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold. International Journal of Cardiovascular Imaging, 2012, 28, 1307-1314.	1.5	13

#	ARTICLE	IF	CITATIONS
91	Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: Can the scaffold cap the plaque?. <i>Atherosclerosis</i> , 2012, 221, 106-112.	0.8	115
92	Different cardiac biomarkers to detect peri-procedural myocardial infarction in contemporary coronary stent trials: impact on outcome reporting. <i>Heart</i> , 2012, 98, 1424-1430.	2.9	27
93	Lipid core burden index and Framingham score: Can a Systemic Risk Score predict lipid core burden in non-culprit coronary artery?. <i>International Journal of Cardiology</i> , 2012, 156, 211-213.	1.7	4
94	Left main coronary intervention: Are we moving too quickly without the appropriate evidence base?. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 80, 213-214.	1.7	0
95	Combined anatomical and clinical factors for the long-term risk stratification of patients undergoing percutaneous coronary intervention: the Logistic Clinical SYNTAX score. <i>European Heart Journal</i> , 2012, 33, 3098-3104.	2.2	138
96	ABSORB II randomized controlled trial. <i>American Heart Journal</i> , 2012, 164, 654-663.	2.7	113
97	Vascular Response of the Segments Adjacent to the Proximal and Distal Edges of the ABSORB Everolimus-Eluting Bioresorbable Vascular Scaffold: 6-Month and 1-Year Follow-Up Assessment. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 656-665.	2.9	35
98	A Global Risk Approach to Identify Patients With Left Main or 3-Vessel Disease Who Could Safely and Efficaciously Be Treated With Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 606-617.	2.9	91
99	Serial 2- and 3-Dimensional Visualization of Side Branch Jailing After Metallic Stent Implantation. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 1089-1090.	2.9	6
100	Relationship Between Palpography and Virtual Histology in Patients With Acute Coronary Syndromes. <i>JACC: Cardiovascular Imaging</i> , 2012, 5, S19-S27.	5.3	23
101	Plaque Compositional Syntax Score. <i>JACC: Cardiovascular Imaging</i> , 2012, 5, S119-S121.	5.3	9
102	Bioresorbable Scaffolds: Current Evidence and Ongoing Clinical Trials. <i>Current Cardiology Reports</i> , 2012, 14, 626-634.	2.9	33
103	Agreement and reproducibility of grayscale intravascular ultrasound and optical coherence tomography for the analysis of the bioresorbable vascular scaffold. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 890-902.	1.7	29
104	Proximal and distal maximal luminal diameters as a guide to appropriate deployment of the ABSORB everolimus-eluting bioresorbable vascular scaffold. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 880-888.	1.7	38
105	Evaluation with in vivo optical coherence tomography and histology of the vascular effects of the everolimus-eluting bioresorbable vascular scaffold at two years following implantation in a healthy porcine coronary artery model: implications of pilot results for future pre-clinical studies. <i>International Journal of Cardiovascular Imaging</i> , 2012, 28, 499-511.	1.5	16
106	Comparison of in vivo eccentricity and symmetry indices between metallic stents and bioresorbable vascular scaffolds: Insights from the ABSORB and SPIRIT trials. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 219-228.	1.7	46
107	Unravelling the complexities of the coronary bifurcation: is this raising a few eyebrows?. <i>EuroIntervention</i> , 2012, 7, 1133-1141.	3.2	10
108	Use of the Sideguard (Cappella) stent in bifurcation lesions: a real-world experience. <i>EuroIntervention</i> , 2012, 7, 1170-1180.	3.2	4

#	ARTICLE	IF	CITATIONS
109	Angiographic maximal luminal diameter and appropriate deployment of the everolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography: an ABSORB cohort B trial sub-study. <i>EuroIntervention</i> , 2012, 8, 214-224.	3.2	51
110	Angiographic and histological results following implantation of a novel stent-on-a-wire in the animal model. <i>EuroIntervention</i> , 2012, 8, 390-399.	3.2	4
111	Transcatheter aortic valve implantation: new developments and upcoming clinical trials. <i>EuroIntervention</i> , 2012, 8, 617-627.	3.2	30
112	Comparison of intravascular ultrasound versus angiography-guided drug-eluting stent implantation: a meta-analysis of one randomised trial and ten observational studies involving 19,619 patients. <i>EuroIntervention</i> , 2012, 8, 855-865.	3.2	163
113	6-Month Clinical Outcomes Following Implantation of the Bioresorbable Everolimus-Eluting Vascular Scaffold in Vessels Smaller or Larger Than 2.5 mm. <i>Journal of the American College of Cardiology</i> , 2011, 58, 258-264.	2.8	44
114	Serial Analysis of the Malapposed and Uncovered Struts of the New Generation of Everolimus-Eluting Bioresorbable Scaffold With Optical Coherence Tomography. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 992-1001.	2.9	75
115	Three-Dimensional Reconstruction of the Post-Dilated ABSORB Everolimus-Eluting Bioresorbable Vascular Scaffold in a True Bifurcation Lesion for Flow Restoration. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 1149-1150.	2.9	16
116	New Insights Into the Coronary Artery Bifurcation. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 921-931.	2.9	53
117	Serial In Vivo Intravascular Ultrasound-Based Echogenicity Changes of Everolimus-Eluting Bioresorbable Vascular Scaffold During the First 12 Months After Implantation. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 1281-1289.	2.9	19
118	Head-to-Head Comparison of the Neointimal Response Between Metallic and Bioresorbable Everolimus-Eluting Scaffolds Using Optical Coherence Tomography. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 1271-1280.	2.9	61
119	3D Reconstructions of Optical Frequency Domain Imaging to Improve Understanding of Conventional PCI. <i>JACC: Cardiovascular Imaging</i> , 2011, 4, 1044-1046.	5.3	5
120	Contemporary and evolving risk scoring algorithms for percutaneous coronary intervention. <i>Heart</i> , 2011, 97, 1902-1913.	2.9	65
121	3-Dimensional reconstruction of a bifurcation lesion with double wire after implantation of a second generation everolimus-eluting bioresorbable vascular scaffold. <i>International Journal of Cardiology</i> , 2011, 153, e43-e45.	1.7	19
122	3-Dimensional optical frequency domain imaging for the evaluation of primary percutaneous coronary intervention in ST-segment elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2011, 151, 103-105.	1.7	11
123	The SYNTAX Score and SYNTAX-Based Clinical Risk Scores. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2011, 23, 99-105.	0.6	22
124	Assessment of coronary atherosclerosis by IVUS and IVUS-based imaging modalities: progression and regression studies, tissue composition and beyond. <i>International Journal of Cardiovascular Imaging</i> , 2011, 27, 225-237.	1.5	38
125	Utilizing Risk Scores in Determining the Optimal Revascularization Strategy for Complex Coronary Artery Disease. <i>Current Cardiology Reports</i> , 2011, 13, 415-423.	2.9	14
126	The use of a guide catheter extension system as an aid during transradial percutaneous coronary intervention of coronary artery bypass grafts. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 78, 847-863.	1.7	45

#	ARTICLE	IF	CITATIONS
127	Angiographic Geometric Changes of the Lumen Arterial Wall After Bioresorbable Vascular Scaffolds and Metallic Platform Stents at 1-Year Follow-Up. JACC: Cardiovascular Interventions, 2011, 4, 789-799.	2.9	48
128	Restenosis. Circulation: Cardiovascular Interventions, 2011, 4, 195-205.	3.9	165
129	A guide to interpreting and assessing the performance of prediction models. EuroIntervention, 2011, 6, 909-912.	3.2	5
130	Optical coherence tomography (OCT) of overlapping bioresorbable scaffolds: from benchwork to clinical application. EuroIntervention, 2011, 7, 386-399.	3.2	37
131	Tools & Techniques: Risk stratification and diagnostic tools in left main stem intervention. EuroIntervention, 2011, 7, 747-753.	3.2	3
132	Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease. American Journal of Kidney Diseases, 2004, 43, 531-537.	1.9	89
133	The severity of muscle ischemia during intermittent claudication. Journal of Vascular Surgery, 2002, 36, 89-93.	1.1	26